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ABSTRACT
The article presents a hypothesis on a co-delivery strategy to
suppress or reduce infection caused by the COVID-19 virus.
Co-delivery was illustrated in many diseases, and results
showed that it produced a high therapeutic efficacy against
disorders. We proposed an approach to suppress or reduce
infection caused by the coronavirus disease 2019 via design-
ing an intelligent nano-liposome loaded with interferon c,
interleukin 4 and small interfering RNA against vimentin. At
the surface of this nanostructure, there is a matrix metallo-
peptidase3 substrate to provide a platform for the enzymatic
function of matrix metallopeptidase3 to destroy the extracel-
lular matrix, angiotensin-converting enzyme 2 blocker, and
antibody against vimentin for targeting, trans-activator of
transcription peptide, and polyethylene glycol. Due to the
increasing application of nano-liposomes commercially as a
drug-delivery system, it is important to consider this effective
approach for the coronavirus disease 2019 treatment.
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Discussion
The recent outbreak of coronavirus disease 2019 (COVID-19), the novel
disease arising from a new coronavirus species, named SARS-CoV-2, has
caused many researchers around the world to find treatment for this
condition. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) caus-
ing severe respiratory diseases, two other known viruses from the same
genera, were identified in 2002 and 2012, respectively. COVID-19, as a
novel virus, seems to have a similar pattern to SARS and MERS
(Mosaddeghi et al. 2020). Innate immune system interactions with the
viral play a key role in determining the outcome of infection. Early con-
trol of viral replication by type I interferons (IFN-I), complement pro-
teins, and other innate immune mediators limit viral spread within the
host during the early phases of the disease (Frieman, Heise, and Baric
2008). IFN-I (IFN-a and IFN-b) has a protective effect on SARS-CoV
and MERS-CoV infection, but the IFN-I pathway in infected mice is
inhibited (Li et al. 2020). Therefore, preventing IFN-I inhibition or load-
ing it into the cell can effectively reduce the virus’s infection.
Angiotensin-converting enzyme 2 (ACE2), the type I integral trans-
membrane protein, was considered the functional receptor for SARS-
CoV both in vitro and in vivo (Yu et al. 2016). Researches in the expres-
sion of ACE2 protein, cellular distributions, and tissue tropism of SARS-
CoV, provided novel insight into the mechanism of pathogenesis. On the
other hand, vimentin has been reported to play roles in viral multiplica-
tion; it interacts directly with SARS-CoV spike protein during the spike-
ACE2 binding process and serves as a putative co-receptor involved in
the entry of SARS-CoV. Vimentin is the major component of type III
intermediate filament protein. Its main purpose is to maintain the archi-
tecture of the cytoplasm. It can also be secreted under certain conditions
and participates in cell adhesion, migration, and cellular signaling (Yu
et al. 2016). Thereby, it seems that controlling or reducing these
receptors’ activity is effective in the treatment of viral infections.
Various delivery systems, such as viral and non-viral vectors, have
been introduced, which has a promising role in gene/drug therapy’s suc-
cess. Non-viral delivery systems reduce immunogenicity and carcinogen-
esis, so they are desirable candidates for gene/drug therapy due to their
well-defined physical and chemical composition. In this regard, cationic
lipids and liposomes display promising advantages, including low tox-
icity, efficient interaction with lipid cell membranes, and enhanced endo-
somal escape. They have been known as suitable carriers for gene/drug
delivery (Mura, Nicolas, and Couvreur 2013).
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Presentation of the hypothesis
Many researchers have started to explore effective treatment strategies
against COVID-19 diseases, Such as discovering effective drugs and vac-
cines. However, the important role of nanotechnology must also be con-
sidered. We proposed an approach to suppress or reduce infection
caused by the COVID-19 virus via designing an intelligent nano-lipo-
some loaded with interferon c, interleukin 4, and small interfering RNA
(siRNA) against vimentin. At the surface of this nanostructure, there is
matrix metallopeptidase3 (MMP3) substrate [to provide a platform for
the enzymatic function of MMP3 for the destruction of extracellular
matrix (ECM)], ACE2 blocker and antibody against vimentin (for target-
ing the desired cells), trans-activator of transcription (TAT) peptide and
polyethylene glycol. The MMP3 substrate, in addition to its important
role in destroying the ECM, also provides a connection site for ACE2
blocker and antibody against vimentin, due to the effects of IFN-I (IFN-
a and IFN-b) on SARS-CoV and MERS-CoV infections, and inhibition
of IFN-I pathway in infected mice, therefore, IFN-I can also be loaded in
nano-liposomes or a mixture of two types of nano-liposomes can be
used, one with IFN-I and the other with IFN-c and IL-4. In the follow-
ing, the reasons for using each of these compounds are explained.
In this regard, a virus-infected cell model has been assumed, and in
parallel, phospholipids have been covalently conjugated to TAT peptide,
MMP3 substrate, anti-vimentin antibody and blocker for ACE2 receptor.
The functional lipids have been mixed to generate intelligent liposomes
containing siRNA and IL-4/IFN-c compounds with high efficiency,
which could be a promising strategy for the treatment of COVID-19.
Several synthesis steps of selected moieties perform the fabrication of
intelligent liposomes with TAT peptide and anti-vimentin antibody to
PEG-conjugated lipids. The TAT peptide enhances the intracellular
uptake and lysosomal escape of the nano-vesicles and increases the intra-
cellular loading of selected siRNA (against vimentin) and IL-4/IFN-c
compounds. Previous studies have shown that cytoplasmic vimentin is
translocated to the cell surface and interacted with the spike-ACE2 com-
plex, revealing a putative entry pathway for SARS-CoV and other viruses
(Du et al. 2014; Yu et al. 2016). Therefore, suppressing vimentin (Both
intracellular and on the cell surface) through siRNA and anti-vimentin
antibody probably disrupts the entry of the virus into the cell.
Different types of angiotensin-converting enzyme inhibitors (ACEIs)
and angiotensin receptor blockers (ARBs) are used for cardiovascular
diseases. It is believed that ACEIs and ARBs increase the numbers of
ACE2 receptors. Several studies have suggested that ACE2 receptors
serve as binding sites for the anchoring spike proteins on the exterior
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surfaces of COVID-19. Accordingly, it has been hypothesized that
patients treated with ACEIs and ARBS, due to increased numbers of
ACE2 receptors, may be at increased risk for COVID-19 infection (Diaz
2020; Li, Hu, and Zhang 2020; Zheng et al. 2020). On the other hand, a
study by De Lang, et al. in 2006 showed that treatment of Vero E6 cells
with interleukin-4 (IL-4) and Interferon-c (IFN-c) downregulate the
expression of the SARS coronavirus receptor ACE2 (de Lang, Osterhaus,
and Haagmans 2006). Since COVID-19 exhibits a very high sequence
homology with SARS-CoV-1, these results can be used for COVID-19
(Kim et al. 2020). Because we have to use ACE2 receptors blocker at the
surface of the nano-liposome for targeting, we can use IL-4 and IFN-c
within the nano-liposomes to neutralize the effect of the blocker on
increasing receptor expression in the target cells.
The studies have shown that coronaviruses inhibit the IFN-I pathway in
infected mice. On the other hand, nuclear transport of IFN regulatory fac-
tor 3 (IRF3) is suppressed by MERS-CoV (Frieman, Heise, and Baric 2008;
Li et al. 2020; Yang et al. 2015), thereby loading of interferon into the
nano-liposomes may have a protective effect on SARS-CoV2 infection, but
here, first of all, our goal is to block the ACE2 receptor and then to prevent
the increased expression of these receptors by the target cells, so we can use
IL-4/IFN-c compounds within the nano-liposomes to neutralize the effect
of the blocker on increasing receptor expression in the target cells.
The MMP3 are zinc-dependent endo-peptidases and comprise a large
family of enzymes with different abilities to degrade specific ECM com-
ponents. Therefore, the use of the MMP3 substrate at the surface of the
nano-liposome provides a platform for the enzymatic function of MMP3
to destroy the ECM. Incorporation of anti-vimentin antibody and ACE2
blocker on the surface of liposomes leads to specific targeting of infected
cells through vimentin, and ACE2 receptors and the presence of MMP3-
cleavable substrate provides enhanced conditions to expose TAT-linked
liposome uptake. On the other hand, co-immunoprecipitation analysis
suggested that MMP3 directly interacted with NFkB in the nucleus dur-
ing DENV infection in Vero E6 and other cells and showed antiviral
activity against DENV infection (Zuo et al. 2014). Therefore, the study of
MMP3 anti-viral activity in COVID-19 infectious cells requires investiga-
tion. PEG is also used in the design of nano-liposomes. Medium-sized
PEG linkers stabilize liposomes and avoid them from aggregation and
without visible steric hindrance, provide sufficient spacer length for the
functional TAT, MMP3, and antibody moieties to interact with their
respective targets (Xia, Tian, and Chen 2016). Our goal is targeted lipo-
somes production that may become a potential tool in gene/drug delivery
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to improve disease control or reduce the activity of factors involved in
the signaling of COVID-19 viral infection.
Testing the hypothesis
For this study, vero E6 cell line, siRNA, IL-4/IFN-c compounds, anti-
vimentin antibody, ACE2 receptor blocker, and also, lipid compounds
including Cholesterol, L-a-phosphatidylcholine, egg, chicken (PC), 1,2-dio-
leoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2- dioleoyl-3 trimethy-
lammonium-propane methyl sulfate salt (DOTAP), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[maleimide(polyethyleneglycol)-2000]
(DSPE-PEG(2000)-maleimide) are supplied from a variety of sources.
Optimized TAT and MMP3 peptide sequences are ordered from reputable
companies. The next step, synthesis, purification, and verification of lipid/
peptide compounds to bind to the nano-liposomes, will be performed. The
hypothesis can be investigated by encapsulating siRNA and IL-4/IFN-c
compounds into liposomes using the thin-film hydration method; then the
following steps are performed: (1) Micelle generation and antibody/blocker
conjugation, (2) Formulation of initial non-targeted liposome containing
siRNA or IL-4/IFN-c compounds, (3) Formulation of targeted liposomes
(4) Cell toxicity, cellular uptake, and competition analysis. It is important to
note that the insertion of the antibody/blocker conjugated micelles into ini-
tial liposomes is applicable by the post-insertion method. Cytotoxicity
effects of nanoparticles will be evaluated after 5 days, using the MTT assay;
also, cellular uptake analysis and gene/protein quantification (including
ACE2 and vimentin) are accomplished using flow cytometry, real-time
PCR, and western blot techniques, respectively.
Implications of the hypothesis
Cationic lipids and liposomes demonstrate promising advantages, such as
low toxicity, efficient interaction with lipid cell membranes, and
enhanced endosomal escape. They have been known as suitable carriers
for gene/drug delivery (Zhi et al. 2018). Nano-liposomes are considered
both as an investigational system and commercially as a drug-delivery
system. Many studies have been conducted on liposomes to decrease
drug toxicity and reduce non-specific cells’ targeting (Akbarzadeh et al.
2013). The conjugation of cell/tissue-specific ligands on the surface of
liposomes efficiently has influenced the potency of gene/drug delivery.
Targeted liposomes improve the tendency to load in infected areas, min-
imize unspecific delivery to other tissues, and facilitate cell-specific treat-
ment. Co-delivery was illustrated in several diseases, including cancer by
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many researchers, and results showed that it produced a higher thera-
peutic efficacy against infections. (Perche and Torchilin 2013). This
hypothesis focuses on the generation of nano-liposome with properties
co-delivery of siRNA and IL-4/IFN-c compounds against the virus-
infected cells. On the other hand, selected key factors (such as an anti-
vimentin antibody, ACE2 blocker, and MMP3 substrate) from various
articles to targeted nano-liposomes fabrication confirms that the target-
ing of the infected cells or areas will be carried out effectively.
In this investigation, a virus-infected cell model is considered, and in
parallel, phospholipids have been covalently conjugated to TAT, MMP3,
anti-vimentin antibody and blocker for ACE2 receptor. The functional
lipids have been mixed to generate intelligent liposomes harboring
siRNA and IL-4/IFN-c compounds with high efficiency, which could be
a promising strategy for the treatment of COVID-19.
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